Innovent Biologics Inc.
IVBXF | OTC
$10.53
+$0.63 (+6.36%)
Nov 2, 2026, 10:30 AM ET · Market open
TTM Period Ending | Q2 2026 Jun 30, 2026 | Q4 2025 Dec 31, 2025 | Q2 2025 Jun 30, 2025 | Q4 2024 Dec 31, 2024 | Q2 2024 Jun 30, 2024 | Q4 2023 Dec 31, 2023 | Q2 2023 Jun 30, 2023 | Q4 2022 Dec 31, 2022 | Q2 2022 Jun 30, 2022 | Q4 2021 Dec 31, 2021 | Q2 2021 Jun 30, 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 15.59B | 13.04B | 11.42B | 9.42B | 7.46B | 6.21B | 5.02B | 4.56B | 4.57B | 4.27B | 4.8B |
Cost of Revenue | 2.97B | 3.08B | 2.7B | 2.41B | 2.12B | 1.81B | 1.46B | 1.38B | 1.38B | 1.22B | 1.01B |
Gross Profit | 12.62B | 9.97B | 8.72B | 7.01B | 5.34B | 4.4B | 3.56B | 3.17B | 3.19B | 3.05B | 3.79B |
Operating Income | 1.87B | 733.62M | 726.85M | -755.87M | -1.7B | -1.68B | -2.39B | -3.12B | -3.17B | -2.7B | -761.58M |
Interest Income | 351.34M | 129.11M | 522.94M | 393.83M | 402.55M | 452.84M | 182.7M | 132.41M | 142.8M | 142.8M | 95.44M |
Pretax Income | 1.53B | 838.92M | 1.21B | -78.62M | -1.28B | -1.14B | -1.43B | -2.17B | -2.64B | -2.64B | -1.26B |
Net Income | 1.22B | 813.57M | 1.13B | -94.63M | -1.28B | -1.03B | -1.37B | -2.18B | -2.68B | -2.73B | -1.39B |
Selling & General & Admin | 7.5B | 6.64B | 5.7B | 5.08B | 4.33B | 3.85B | 3.34B | 3.43B | 3.84B | 3.43B | 2.54B |
Research & Development | 3.28B | 2.62B | 2.29B | 2.68B | 2.7B | 2.23B | 2.62B | 2.87B | 2.52B | 2.32B | 2.02B |
Other Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 10.78B | 9.26B | 7.99B | 7.77B | 7.04B | 5.57B | 5.07B | 5.43B | 5.9B | 5.78B | 5.1B |
Interest Expense | 58.38M | 18.03M | n/a | n/a | n/a | n/a | n/a | 44.57M | 157.07M | 139.61M | 27.1M |
Selling & Marketing Expenses | 3.34B | 5.71B | 4.84B | 4.35B | 3.63B | 3.1B | 2.54B | 2.59B | 2.93B | 2.62B | 1.98B |
Cost & Expenses | 13.75B | 12.34B | 10.7B | 10.18B | 9.16B | 7.37B | 6.53B | 6.81B | 7.28B | 7B | 6.11B |
Income Tax Expense | 316.14M | 25.36M | 78.77M | 16.01M | 497K | -116.5M | -59.72M | 8.8M | 38.44M | 87.04M | 136.33M |
Shares Outstanding (Basic) | 1.73B | 1.71B | 1.69B | 1.63B | 1.62B | 1.58B | 1.54B | 1.52B | 1.46B | 1.45B | 1.45B |
Shares Outstanding (Diluted) | 1.8B | 1.79B | 1.69B | 1.63B | 1.62B | 1.58B | 1.54B | 1.52B | 1.47B | 1.46B | 1.45B |
EPS (Basic) | 0.71 | 0.48 | 0.67 | -0.06 | -0.80 | -0.65 | -0.91 | -1.46 | -1.82 | -1.88 | -0.98 |
EPS (Diluted) | 0.67 | 0.48 | 0.67 | -0.06 | -0.80 | -0.65 | -0.91 | -1.46 | -1.82 | -1.88 | -0.98 |
EBITDA | 2.63B | 1.31B | 660.9M | -480.28M | -990.62M | -1.29B | -2.08B | -2.88B | -2.98B | -2.54B | -663.59M |
EBIT | 1.87B | 733.62M | 418.48M | -755.87M | -1.28B | -1.56B | -2.39B | -3.12B | -3.17B | -2.7B | -761.58M |
Depreciation & Amortization | 753.34M | 576.53M | 242.42M | 275.6M | 286.8M | 275.6M | 312.14M | 245.09M | 192.89M | 165.4M | 97.99M |
Add to Watchlist
Select watchlists to add or remove IVBXF